Executive Brief

News Report

The News: ACC updates HFpEF management guidelines to include SGLT2 inhibitors and GLP-1 agonists.
Clinical Win: New guidelines support evidence-based treatment options for HFpEF patients.
Target Specialty: Cardiology

Key Data at a Glance

SGLT2 Inhibitors Efficacy: 21% reduction in heart failure hospitalizations
GLP-1 Agonists Benefits: Cardiovascular protection and weight loss

The American College of Cardiology (ACC) has updated its guidelines for the management of heart failure with preserved ejection fraction (HFpEF), emphasizing the role of SGLT2 inhibitors and GLP-1 receptor agonists in treatment strategies. This update, announced in May 2026, is significant for healthcare providers as it reflects the latest evidence in optimizing care for patients with HFpEF, a condition affecting millions worldwide.

Clinical Context

Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome characterized by the heart's inability to fill adequately, despite normal ejection fraction. It is associated with significant morbidity and mortality, particularly in older adults and those with comorbid conditions such as obesity and diabetes. Current treatment strategies primarily focus on managing symptoms and comorbidities, but there has been a notable gap in effective pharmacotherapy aimed at improving outcomes. Recent studies have shown that SGLT2 inhibitors, initially developed for diabetes management, can significantly reduce hospitalization rates and improve quality of life in HFpEF patients. Similarly, GLP-1 receptor agonists, known for their weight loss benefits and cardiovascular protective effects, are gaining traction as adjunctive therapies. The ACC's updated guidelines aim to integrate these findings into clinical practice, providing a structured approach to treatment.

Key Findings

The ACC guidelines recommend SGLT2 inhibitors as first-line therapy for patients with HFpEF, based on evidence showing a 21% reduction in heart failure hospitalizations compared to placebo [1].

GLP-1 receptor agonists are also endorsed for their cardiovascular benefits, particularly in patients with obesity or type 2 diabetes, aligning with recent WHO recommendations [4].

The updated algorithm emphasizes a personalized approach, considering patient-specific factors such as comorbidities and renal function when selecting treatment options.

The guidelines highlight the importance of lifestyle modifications, including dietary changes and increased physical activity, as foundational elements of HFpEF management.

What This Means for Clinical Practice

The updated ACC guidelines provide a clear framework for clinicians managing patients with HFpEF, emphasizing the integration of SGLT2 inhibitors and GLP-1 receptor agonists into treatment plans. For healthcare providers, this means adopting a more proactive approach to pharmacotherapy, particularly in patients with comorbid obesity or diabetes, where these agents can offer dual benefits. Additionally, the emphasis on lifestyle modifications reinforces the importance of a holistic treatment strategy. Clinicians should be prepared to educate patients about the benefits of these medications, monitor for potential side effects, and adjust treatment plans based on individual patient responses. As the landscape of HFpEF management evolves, staying informed about these guidelines will be crucial for optimizing patient outcomes and improving quality of care.

Clinical Perspective

Workflow: Clinicians should integrate SGLT2 inhibitors and GLP-1 agonists into treatment plans for HFpEF patients, focusing on personalized care.

Economics: Adopting these therapies may reduce hospitalization costs associated with HFpEF management.

Patient Outcomes: Improved pharmacotherapy options are expected to enhance quality of life and reduce morbidity in HFpEF patients.

Dr. Arjun Sharma, Cardiology

ACC Updates HFpEF Guidelines: SGLT2 Inhibitors and GLP-1 Agonists Recommended

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Cardiology in your inbox.

Related Drug Updates

Baxdrostat Reduces Resistant Hypertension: New Treatment Algorithm for 2026

FDA Approves Semaglutide for PAD: STRIDE Trial Shows Improved Walking Distance

Aficamten Reduces Symptoms by 30% in Obstructive HCM: 2025 Clinical Algorithm Update

Verified HCP Portal